ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference

GlobeNewswire06-18

CEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI™ Therapy during main stage presentation EINDHOVEN, the Netherlands, June 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444173271?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vC9oBHWunWH4beq4E3m.1w--~B/aD02MTI7dz0yMjMyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4a683cf0e277e76c7f772244593d1c78","is_english":true,"pubTime":"2024-06-18 13:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2444173271","market":"us","top_or_hot":-1,"title":"ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference","media":"GlobeNewswire","content":"<div>\n<p>CEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI™ Therapy during main stage presentation\nEINDHOVEN, the Netherlands, June 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N....</p>\n\n<a href=\"https://finance.yahoo.com/news/onward-medical-highlight-brain-computer-053000380.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 13:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/onward-medical-highlight-brain-computer-053000380.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI™ Therapy during main stage presentation\nEINDHOVEN, the Netherlands, June 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N....</p>\n\n<a href=\"https://finance.yahoo.com/news/onward-medical-highlight-brain-computer-053000380.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SCI","symbol_name":"Service Corp International","start_time":0,"source_url":"https://finance.yahoo.com/news/onward-medical-highlight-brain-computer-053000380.html","article_id":"2444173271","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vC9oBHWunWH4beq4E3m.1w--~B/aD02MTI7dz0yMjMyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4a683cf0e277e76c7f772244593d1c78"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444173271","pubTimestamp":1718688600,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"CEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI Therapy during main stage presentation. CEO Dave Marver and trial participant Gert-Jan Oskam will address conference attendees in a keynote on the main stage on June 19, 2024. The pair will discuss how investigational ARC-BCI Therapy uses artificial intelligence to enable thought-driven movement after paralysis, the future of therapies to treat SCI, and Gert-Jan's experience as the first human to be implanted with a brain-computer interface to restore walking.Use of non-invasive ARC-EX Therapy significantly improved upper limb function after SCI in the global pivotal Up-LIFT trial, with results published byNature Medicinein May 2024. The Company has submitted its regulatory application to the FDA for clearance of the ARC-EX System in the US and is preparing for regulatory submission in Europe. In parallel, the Company is conducting clinical studies with its ARC-IM Therapy, which demonstr","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SCI":"Service Corp International","ONWRF":"Onward Med NV","BK4192":"特殊消费者服务","TILE":"Interface Inc.","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4082":"医疗保健设备","BK4548":"巴美列捷福持仓","BCI":"abrdn Bloomberg All Commodity Strategy K-1 Free ETF","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4143":"办公服务与用品","HLTH":"Cue Health Inc."},"translate_title":"®医疗将在HLTH欧洲会议上重点介绍脑机接口","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCI":1,"HLTH":1,"SCI":1,"TILE":1,"ONWRF":0.9},"content_text":"CEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI™ Therapy during main stage presentation\nEINDHOVEN, the Netherlands, June 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that the Company will be highlighted in a main stage keynote at HLTH Europe, a premier event for digital health leaders. The conference takes place June 17-20 in Amsterdam, the Netherlands.\nCEO Dave Marver and trial participant Gert-Jan Oskam will address conference attendees in a keynote on the main stage on June 19, 2024. The pair will discuss how investigational ARC-BCI Therapy uses artificial intelligence to enable thought-driven movement after paralysis, the future of therapies to treat SCI, and Gert-Jan's experience as the first human to be implanted with a brain-computer interface to restore walking.\nMore than 3500 leaders are expected to attend this year’s inaugural HLTH Europe, which began in the US, where it is one of the leading health innovation conferences in the country.\nTo learn more about ONWARD Medical’s commitment to partnering with the SCI Community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.\n*All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.\nAbout ONWARD Medical   \nONWARD® Medical is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of scientific discovery, preclinical, and clinical research conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy™, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA).\nONWARD ARC Therapy is targeted, programmed spinal cord stimulation designed to be delivered by the Company’s external ARC-EX® or implantable ARC-IM® platforms. ARC Therapy can also be delivered by the Company’s ARC-BCI™ platform, which pairs the ARC-IM System with brain-computer interface (BCI) technology to restore movement after SCI with thought-driven control.\nUse of non-invasive ARC-EX Therapy significantly improved upper limb function after SCI in the global pivotal Up-LIFT trial, with results published by Nature Medicine in May 2024. The Company has submitted its regulatory application to the FDA for clearance of the ARC-EX System in the US and is preparing for regulatory submission in Europe. In parallel, the Company is conducting clinical studies with its ARC-IM Therapy, which demonstrated positive interim clinical outcomes for improved blood pressure regulation following SCI. Other ongoing clinical studies focus on using ARC-IM Therapy to address mobility after SCI and gait challenges in Parkinson’s disease as well as using the ARC-BCI platform to restore thought-driven movement of both upper and lower limbs after SCI.    \nHeadquartered in Eindhoven, the Netherlands, ONWARD Medical has a Science and Engineering Center in Lausanne, Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Brussels and Amsterdam (ticker: ONWD).\nFor more information, visit ONWD.com, and connect with us on LinkedIn and YouTube.\nFor Media Inquiries:   Aditi Roy, VP Communications  media@onwd.com \nFor Investor Inquiries:  Amori Fraser, Finance Directorinvestors@onwd.com   Disclaimer  \nCertain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. All ONWARD Medical devices and therapies referenced here, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™ and ARC Therapy™, are investigational and not available for commercial use.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444173271"}